CORD-19:3c1f47a07aaf0e393dee9fbd08596a4b9f4f0a03 / 288611-288821
Annnotations
CORD-19-Sentences
{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T2238","span":{"begin":0,"end":210},"obj":"Sentence"},{"id":"T77544","span":{"begin":0,"end":210},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"During hospitalisation, 15% VANC cases subsequently received MET, and 12% MET received VANC; 9% MET and 11% VANC received IV MET (unknown if specifically for CDAD), and 1.5% MET and 3.1% VANC received rifampin."}
CORD-19_Custom_license_subset
{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T337","span":{"begin":0,"end":210},"obj":"Sentence"}],"text":"During hospitalisation, 15% VANC cases subsequently received MET, and 12% MET received VANC; 9% MET and 11% VANC received IV MET (unknown if specifically for CDAD), and 1.5% MET and 3.1% VANC received rifampin."}
Epistemic_Statements
{"project":"Epistemic_Statements","denotations":[{"id":"T619","span":{"begin":0,"end":210},"obj":"Epistemic_statement"}],"text":"During hospitalisation, 15% VANC cases subsequently received MET, and 12% MET received VANC; 9% MET and 11% VANC received IV MET (unknown if specifically for CDAD), and 1.5% MET and 3.1% VANC received rifampin."}